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Background: Respiratory tract infections are an important burden in primary care and it’s known that they are
usually self-limited and that antibiotics only alter its course slightly. This together with the alarming increase of
bacterial resistance due to increased use of antimicrobials calls for a need to consider strategies to reduce their use.
One of these strategies is the delayed prescription of antibiotics.
Methods: Multicentric, parallel, randomised controlled trial comparing four antibiotic prescribing strategies in acute
non-complicated respiratory tract infections. We will include acute pharyngitis, rhinosinusitis, acute bronchitis and
acute exacerbation of chronic bronchitis or chronic obstructive pulmonary disease (mild to moderate). The
therapeutic strategies compared are: immediate antibiotic treatment, no antibiotic treatment, and two delayed
antibiotic prescribing (DAP) strategies with structured advice to use a course of antibiotics in case of worsening of
symptoms or not improving (prescription given to patient or prescription left at the reception of the primary care
centre 3 days after the first medical visit).
Discussion: Delayed antibiotic prescription has been widely used in Anglo-Saxon countries, however, in Southern
Europe there has been little research about this topic. The DAP trial wil evaluate two different delayed strategies in
Spain for the main respiratory infections in primary care.
Trial registration: This trial is registered with ClinicalTrials.gov, number NCT01363531.
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Infectious diseases are among the most common com-
plaints for family physicians. About 70% of these are
respiratory tract infections, and the most common infec-
tions are acute bronchitis, pharyngitis and rhinitis [1].
Most of the respiratory tract infections are self-limiting,
and according to recent systematic reviews, antibiotics
have only a small effect on the course of most of these
infections [2-10].
Besides, antibiotic treatment is no free of downsides
including adverse events, increasing the costs for the
same episode, and reinforcing beliefs about their useful-
ness. It has also been observed that antibiotic prescrib-
ing in respiratory tract infections correlates with a
higher frequency of visits to the physician in the future,
thus rising patients’ expectations about their use [11].
More importantly, though, the appearance and increase
of bacterial antibiotic resistance is attributed mainly to
the overuse of antibiotics [12]. This is a fundamental as-
pect since it may be increasingly more difficult to treat
infections.
On the other hand, there is great variability in anti-
biotic prescribing among professionals, communities,
and countries. Spain is one of the countries with the
highest rate of antibiotic prescribing [13] and the rate of
inappropriate antibiotic prescribing is also high, implying
inappropriate use of resources [14,15].
Nevertheless, sometimes avoidance of antibiotic pre-
scribing is still a challenge in patients with uncompli-
cated respiratory tract infections. Firstly, because it is
not known which patients are at a higher risk of devel-
oping complications that, though uncommon, might be
serious. Secondly, there are patients who wish and ex-
pect to be prescribed an antibiotic if symptoms do not
subside [16], and physicians that overestimate the pro-
portion of patients who expect be treated with antibi-
otics [17]. For these reasons, complete avoidance of
antibiotic prescribing in patients with uncomplicated
respiratory tract infections is not appropriate.
Several studies have shown that the interventions
aimed at reducing antibiotic prescribing may result in
lower prevalence of resistant strains [12]. One of these
interventions is the delayed prescription of antibiotics,
in which the patient is prescribed an antibiotic that
should be taken only in case of worsening of the symp-
toms or no improvement a few days after the visit. This
strategy has been used in conditions where it may be dif-
ficult to differentiate between a viral and a bacterial eti-
ology in primary care settings, such as respiratory tract
infections and other infections such as conjunctivitis
[18] or urinary tract infections [19].
A systematic review [20], concludes that delayed anti-
biotic prescription reduces antibiotic use without an in-
crease in complications of these conditions, with littleadvantage compared with the non-prescription. This re-
view shows how immediate compared to delayed anti-
biotic prescribing is associated with a consistently higher
patient satisfaction. Additionally, other studies suggest
that this strategy might reduce the number of visits
[11,16] since patients can get rapid access to antibiotics
in case of no improvement. Besides, as indicated by an-
other systematic review [21] family doctors see this strat-
egy as an intervention that may help them resolve
uncertainties. Similarly, family doctors believe that reas-
sures patients, providing them with control over their
conditions and allowing them to reconcile with their
expectations.
Despite the advantages seen in other parts of the
world, no studies have evaluated the effectiveness and
the acceptability of delayed prescription in Southern
Europe. Only a single observational study [22] showed
that this strategy might reduce antibiotic prescribing by
33%. For these reasons, we designed a multicenter, ran-
domized clinical trial to assess delayed prescription in
Spain.
The aim of this study is to establish the effectiveness
of delayed antibiotic prescribing strategies versus anti-
biotic therapy and no therapy in terms of duration and
severity of symptoms. Therefore, the study will establish
the effectiveness of delayed antibiotic prescribing strat-
egies versus antibiotic therapy and no therapy in terms
of: antibiotic use at 30 days, satisfaction and belief in
antibiotic effectiveness.
Methods
Multicenter, randomized controlled clinical trial (Phase
IV) comparing four therapy strategies for uncomplicated
acute respiratory tract infections (clinicaltrials.gov, iden-
tifier NCT01363531).
Randomization
Stratified by condition of interest (pharyngitis, rhinosinusitis,
acute bronchitis, and exacerbations of chronic obstructive
pulmonary disease). Centralized using a Web-based
platform.
Masking
Open-label study given the type of strategies used and
given that an effect on their beliefs and the antibiotic
use is expected.
Experimental and control groups
Four treatment arms:
a) Group 1: immediate antibiotic therapy.
b) Group 2: no antibiotic therapy.
c) Group 3: delayed prescription by handing the
prescription to the patient.
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prescription at the health care center from the third
day after the initial visit.
The inclusion of no antibiotic and immediate anti-
biotic strategies is due to the need to evaluate their rela-
tive effectiveness compared with the delayed strategies.
Potential differences among the delayed strategies are
assessed by comparing the two delayed prescription
strategies.
The choice of antibiotic therapy will depend on the
specific respiratory tract condition and will be up to the
physicians’ judgement, according to their usual clinical
practice. Physicians will also handle symptomatic treat-
ment and complications as needed.
Inclusion and exclusion criteria
Patients over 18 years old with uncomplicated acute re-
spiratory tract infections will be enrolled: acute pharyn-
gitis, rhinosinusitis, acute bronchitis, and exacerbations
of chronic bronchitis/mild to moderate chronic ob-
structive pulmonary disease. Patients with these infec-
tions will be included by the physicians as long as they
are unsure of whether to use antibiotics or not. See de-
tails of the general and specific study criteria for each
condition under [see Additional file 1].
Study population and total number of patients
The sample size calculated is 600 patients. This is an es-
timate based on an average duration of 12 days (s.d. 6)
for the main symptoms [16]. Considering a reduction of
two days in the duration of the symptoms as a clinically
relevant outcome, with a bilateral approximation, a sam-
ple of 600 patients will be able to detect this difference
with an alpha error of 5% and a power of 80% (beta =
0.2). This estimate was calculated considering lower re-
spiratory tract infections only. The project aims to be
much broader (and therefore pragmatic, with an increase
in the external validity at the conceptual phase), for this
reason an exhaustive search will be carried out for all
the conditions initially expected to be included (pharyn-
gitis, rhinosinusitis, acute bronchitis, acute exacerbation
of chronic bronchitis). The aim of this search is to ob-
tain average values of the main endpoints defined in this
project and to allow for standardization, and accord-
ingly, a comparison (the variability that can be derived
from the data obtained for the calculation has reached
50%, which indicates a high dispersion). It seems un-
likely that the remaining conditions exceed that value,
and generally, they will even tend to be lower. This al-
lows avoiding the estimation of losses in the required
total number of patients.
The patients will be equally distributed among the four
evaluation groups to maximize power in the comparison.In addition, the four groups will be stratified in terms of
the included conditions. Besides, focusing on the three
groups except for the immediate antibiotic therapy, the
450 patients distributed in the three arms would allow
to detect a difference of at least 13% in antibiotic use
with the same indicated power (assuming that the fig-
ures for antibiotic use in the two delayed strategies are
very similar: delayed strategy group 27% versus 14% in
the group with no antibiotic therapy). Finally, in the
comparison of four strategies for the variable antibiotic
use, the study will have a 100% for antibiotic use as an
outcome, since the percentage of antibiotic use in the
antibiotic therapy arm is likely to exceed 90%. For the
calculations we used Sample Power Release 2.0 software.
Criteria for withdrawals and expected analysis of with-
drawals and dropouts:
 Serious adverse event
 Unsatisfactory therapeutic effect
 Patient clinical conditions prevent compliance with
the protocol
 Protocol violation
 Informed consent withdrawal
Patients can choose to interrupt the medication any
time during the course of the study. However, they
will be followed up in the same way as the other
patients. Analyses will follow the intention-to-treat
principle, with patients being analysed in the groups
to which they were randomized.
Outcome variables
A)Main effectiveness endpoint
Duration and severity of symptoms. Patients will
complete a validated symptom questionnaire daily
[see Additional file 2] [16].
B) Secondary effectiveness endpoints
The following variables will be assessed:
– Use of antibiotics: patients will be asked about
antibiotic use in their visit at 30 days and this will
be crosschecked with the corresponding
pharmacy units in the sanitary areas.
– Satisfaction with the strategy (questionnaire with
a Likert scale to patients).
– Belief in the effectiveness of antibiotics
(questionnaire with a Likert scale to patients and
health professionals).
– Perception about safety and effectiveness
(questionnaire with a Likert scale to health
professionals).
C) Safety endpoints
Complications related to the infections will be
registered during the first 30 days after
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prospectively recorded by the physicians by means
of a standardized questionnaire and will be reported
in a maximum of 48 hours to the study clinical
coordinator. This researcher will report to the Safety
and Data Monitoring Committee, whose aim is to
assess the safety of the evaluated strategies. The
Clinical Event Allocation Committee - blinded to
treatment allocation - will assess the primary
outcomes. The decisions of the Assessment
Committee will be used in all the statistical analyses
of the primary outcome. This Committee will meet
quarterly.Enrollment
Enrollment will be carried out competitively at the par-
ticipating physicians’ clinics and is expected to take one
year. The study will be carried out in five Spanish Au-
tonomous Communities (Catalonia, Galicia, Basque
Country, Navarre and Madrid).
Data collection
Initial visit
Baseline data will be collected in the clinic by the physician
or with the help of the nursing staff. To standardize data
collection, participants will be trained by the coordinating
center. Patients will receive information about the study
and, if they are interested in participating, an informed con-
sent to read and sign will be handed to them. A maximum
length of 10–15 minutes is expected for the interview and
the introduction of the data.
After the randomization, information on the strategy
to which they have been allocated will be given to the
participants, and they will be informed on the appropri-
ate measures to take in case of worsening or no im-
provement. Besides, they will be given a diary with a
validated questionnaire of symptoms for each condition
[16] which they should complete while symptoms related
to the respiratory condition are present [see Additional
file 2]. The degree of satisfaction or concern with differ-
ent aspects of the therapy will also be recorded in this
diary.
Follow-up
Patients will be interviewed by telephone after 48 hours
of their inclusion in the study. Monitoring calls are also
planned at day 7, 15 and 22 if symptoms are still
reported by the patient on the calls. After 30 days, pa-
tients will visit their physician and then will submit the
completed diary. We will also include a one year follow-
up.
All the study data will be entered in an electronic plat-
form (www.grupopreada.com).Data analysis
In order to ensure their similarities, a baseline compari-
son of the treatment groups will be performed. If any
clinically relevant differences are found, a multivariate
analysis will also be performed to ensure the absence of
biases resulting from them. Differences will be deemed
significant if p < 0.05. The SPSS software version 21.0
will be used for the calculations.
The comparisons among the treatment groups will be
as follows: The differences for categorical variables will
be described using contingency tables (and the corre-
sponding percentages); inferencing will be made by
means of an exact Fisher test or Chi-square test. The
Kruskall-Wallis test will be used for ordinal or quantita-
tive variables with heteroscedasticity or abnormality is-
sues. In case of significance, the decision on the groups
will be based on the 2 × 2 Mann–Whitney test; no cor-
rections will be applied for multiple comparisons, calcu-
lated the means and the higher and lower values for
each group. For quantitative variables, the analysis of
variance (ANOVA) test will be used, resorting to post-
hoc in case of significance, thus showing the means and
the standard deviations for each group.Ethical issues
The protocol was approved by the Ethics Committee of
Clinical Investigation IDIAP Jordi Gol i Gurina and by
the Ethical Committees of Clinical Research in the cor-
responding health care areas and Spanish Agency of
Medicines and Health Products. Each patient should
give their written consent to participate in the study
after being informed in intelligible language for him on
the nature, scope and possible consequences of the trial.
After consent is submitted, the patients will be
randomized.
Data confidentiality will be ensured at all times, as it is
stated in the researcher’s commitment sheet, as well as
the compliance with current legislation regarding the
protection of personal data. The clinical trial will be in-
sured by the health provider to which the different par-
ticipating health centers belong.Other considerations
This is a clinical trial based on the outpatient setting,
and no monetary compensation is given to either pa-
tients or researchers. Sponsorship is only reserved for
the purposes of organization and implementation of the
trial.
Discussion
The main issue addressed in our study is the effectiveness of
the delayed antibiotic prescribing strategy in uncomplicated
respiratory infections. To achieve this we will compare two
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prescribing and no prescription. Specifically, symptom dur-
ation and severity, patient satisfaction, belief in the effective-
ness of antibiotics and antibiotic use in the different
strategies will be assessed.
There are two main types delayed strategies. One
where patients are asked to return to the reception of
the primary health center in order to collect the pre-
scription, and another one in which the prescription is
handed in the initial visit. The rationale for the former
being that asking the patient to return could further re-
duce subsequent use of antibiotics [13,23].
Delayed antibiotic prescribing has been used not only for
respiratory tract infections but also for other types of dis-
eases [18,19]. So far, these studies have shown [20], that
these strategies reduce antibiotic use. As to patients’ satisfac-
tion, a qualitative study in patients with conjunctivitis
showed that this strategy is usually well received [18] and
another in women with urinary tract infections [19] showed
positive perceptions too. In one of them there is the paradox
that those patients who know that their condition is mild
but still feel that they need them, given their strong belief in
the need of a therapy [18]. As to the physicians [21], they
highlight that these strategies can be of help in cases of un-
certainty, since patients can gain fast access to antibiotics
and in addition, the strategy reassures them too.
In our study the two delayed strategies will be com-
pared with other alternatives and with each other. We
also wish to find out whether they are effective redu-
cing the number of new visits. Antibiotic prescribing
in the clinic leads to a vicious circle in which the pa-
tient perceives that an antibiotic treatment is neces-
sary, it increases the number of new visits for the
same reason and increases the chance of requesting a
new antibiotic in similar episodes in the future [11].
Consequently, we will evaluate differences among the
delayed prescribing strategies in terms of the number
of new visits and the immediate antibiotic prescribing
strategy.
Delayed strategies are also criticized for an increased
possibility of complications. In order to avoid them, it is
crucial to bear in mind that these are not used in the
case of patients presenting with supposedly bacterial in-
fections, and reserved in the event of reasonable uncer-
tainty. They should not be used in critically ill patients or
those meeting criteria for admission [24].
Two systematic reviews have studied the use of de-
layed strategies and both have showed significant ad-
vantages. One of them [23] showed that for most of
the symptoms no significant differences in duration
have been observed compared with immediate anti-
biotic prescribing. In a more recent systematic review
Spurling et al showed that delayed prescription sig-
nificantly reduces antibiotic consumption [20].Further studies [25] conclude that delayed prescribing is
an acceptable option, reflected in small differences in terms
of the resolution of the symptoms, and a considerable re-
duction in antibiotic use and in the confidence in its effect-
iveness. The number of randomized patients is still scarce
and the results for some of the outcome are non conclusive.
Nevertheless, some institutions such as NICE start to rec-
ommend it as an initial strategy for self-limiting respiratory
tract infections [26].
Our study has several strengths but also some limitations.
For example, the open-label design of the trial could imply a
placebo effect favoring antibiotics. This effect is minimized
given the structured approach that physicians will apply to
support and increase the confidence in each strategy. In pre-
vious studies this placebo effect has been minimal in favor
of antibiotics or has not been recorded [11,25]. Another
limitation in our study is the absence of a unique consensus
definition for respiratory tract infections. Due to this, we will
use the definitions used in the main published cohort stud-
ies [27].
One of the important strengths of our study is the inclu-
sion of all the main respiratory tract infections, considering
for the first time the exacerbations of mild to moderate
COPD. Besides, it will be the first study to compare two
delayed strategies directly. The pragmatic character of the
study increases the external validity of the results and this
is of special interest to our health system priorities.
The confirmation of our hypothesis will likely reassure
physicians about the effectiveness and safety of these de-
layed strategies. This fact could facilitate their imple-
mentation in our country and, thus, help optimizing
antibiotic prescribing. We believe that our results will
likely help to change patients’ perception about the role
and need of antibiotics.
The impact of our trial is likely to be important since
the available evidence in this field is still limited, and new
larger studies, adequately designed and conducted, are
warranted to clarify the effectiveness of these strategies.
Similarly, including most of the uncomplicated respiratory
infections will increase the external validity of the results.
Comparing, for the first time, two delayed strategies will
provide information on the possible differences within this
modality. These characteristics make this study innovative
and relevant to this field.Additional files
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